First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before breast cancer worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib.<img src="http://feeds.feedburner.com/~r/sciencedaily/~4/N89X72DQTTw" height="1" width="1"/>
